News

As spinal cord stimulation and peripheral nerve stimulation technologies continue to advance, one feature that remains a consistent focus of clinical discussion—and a key differentiator among devices—is the ability (or lack thereof) for patients with active implantable systems to safely undergo MRI scans. Even as far back as the mid-1990s, when this editor was first involved in the cochlear implant…

Neurotech Business Report Neurotech Reports’ 2025 Bioelectronic Medicine Forum at the New York Academy of Medicine convened industry pioneers, investors, and innovators to explore the evolving landscape of bioelectronic medicine. The event illuminated both the challenges and transformative opportunities shaping this dynamic field, offering a blend of cautious optimism, regulatory insights, and groundbreaking technological advancements.

The field of neuromodulation has seen a number of therapeutic and commercial success stories in the 25 years that we have been publishing this newsletter. When a new therapy or commercial device experiences a successful outcome, there is no shortage of coverage in the general press, in scientific journals, and at clinical society meetings. But when a device or therapy experiences failure, there is often very little coverage of what went wrong.

The field of neuroprosthetics has seen a number of advancements in recent months, as investigators at research institutions in the U.S. and Europe have reported progress, and as device firms active in the space have announced product enhancements and other commercialization milestones. On the research front, European and American investigators reported breakthroughs in two areas impacting individuals with spinal cord injury: restoring locomotion and restoring sensation.

About 120 neurotech industry professionals attended the 24th annual Neurotech Leaders Forum in San Francisco earlier this month. Keynote speaker Ray Cohen, CEO of Axonics Inc., gave a timely and evocative keynote address on the first day of the conference, just days before Boston Scientific’s $3.7 billion deal for Axonics closed. Cohen provided a number of details from his tenure at Axonics culminating with the Boston Scientific deal, but he also offered words of advice to neurotech startups.

Neurotech Reports, the publisher of the newsletter Neurotech Business Report , announced the availability of a new market research report that forecasts the growth of the worldwide market for implanted pain neuromodulation systems. According to the newly published report, The Market for Implanted Pain Neuromodulation Systems: 2025-2030, the worldwide market will be $3.37 billion in 2025, growing to $6.49 billion by 2030, which represents a 12% compound annual growth rate.

Neurotech Business Report Executives from several neurotechnology firms joined hundreds of other medtech professionals at the LSI USA 25 conference, held in Dana Point, CA earlier this month. The conference featured several keynotes and panel discussions related to investment, partnering, reimbursement, and other key topics. Lisa Earnhardt, group president of medical devices at Abbott, gave a keynote on the second day of the meeting.

Promising Firms to Present at 2025 Bioelectronic Medicine Forum in NYC Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that several new startup and emerging bioelectronic medicine firms will present at the the Eighth Annual Bioelectronic Medicine Forum. The event will take place on April 10, 2025 at the New York Academy of Medicine in Manhattan.

June, 2004 issue The competitive landscape of the neurotechnology industry changed dramatically this month when Boston Scientific Corp., the Natick, MA manufacturer of medical devices, acquired 100 percent of the stock of Advanced Bionics Corp., the Valencia, CA manufacturer of neural prostheses and neuromodulation devices. The acquisition transforms the industry overnight from one dominated by a s…

The neurotech market for treating psychiatric disorders has proven to be rewarding and elusive at the same time. After some well publicized clinical trial failures of DBS therapies, and an excruciating reimbursement timeline for VNS systems, the implanted neuromodulation device industry is poised to rebound. Abbott’s TRANSCEND study of DBS for treatment-resistant depression seems likely to succeed where predecessor St.